Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes have?
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes has 12,121 citations in the OpenAlex counts ScholarIQ stores.
When was Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes published?
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes has 2015 year in the ScholarIQ index.
What is the open-access status of Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes?
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes has bronze oa status in the ScholarIQ index.
What is the DOI of Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes?
The DOI for Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes is on the source record.
What is the PMID of Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes?
The PMID for Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes is on the source record.
What is the OpenAlex record for Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes?
The OpenAlex for Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes is on the source record.